This trial looks at the long-term safety of a medicine called pirtobrutinib. It is for people with Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma who have already been treated. Participants from an earlier study can continue to receive this medicine and follow up on their health.
The trial's ID number is NCT06876662. This is a Phase 4 trial, which means it is looking at how well the treatment works and how safe it is. About 279 participants are expected to join, and the treatment is regulated by the FDA.
Who can join
Adults aged 18 and older can join. Both men and women are welcome. You must be active in the earlier study to participate. If you were in a specific earlier group, you cannot join this trial. The trial team will confirm eligibility.
The study team makes the final call on eligibility.
What happens in the study
Participants will receive pirtobrutinib, which they will take by mouth. Everyone in this study will get the same treatment. There is no random assignment or separate groups.
Where
This trial is enrolling at 18 locations. Recruiting sites are listed first.
Dana-Farber Cancer Institute
Boston, Massachusetts
Recruiting
Duke University Medical Center
Durham, North Carolina
Recruiting
Florida Cancer Specialists
Sarasota, Florida
Recruiting
Mayo Clinic- Minnesota
Rochester, Minnesota
Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin
Recruiting
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York
Recruiting
Northwell Health
Lake Success, New York
Recruiting
Northwestern University
Chicago, Illinois
Recruiting
Study contact
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Elected to the National Academy of Medicine. Treats leukemia and myelodysplastic syndrome. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.
Professor and transplant specialist, UC Davis. Treats leukemia, lymphoma and multiple myeloma. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.